Orotic Acid

Orotic Acid

SCHEMBL165966

ClCc1ccc2c(c1)CCNCC2.O=C(O)c1cc(=O)[nH]c(=O)[nH]1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
GPR84 Q9NQS5 2/20 0.39
MLNR O43193 6/20 0.37
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
CYP2C19 P33261 1/20 0.35
CYP2D6 P10635 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TSHR P16473 1/20 0.34
ACHE P22303 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Orotic Acid SCHEMBL175081 0.82 ALDH1A1 (0.62) ALDH1A1LMNAGPR84HTR2CHTR2B
Malonic Acid SCHEMBL173339 0.78 HTR2C (0.45) MLNRHTR2AHTR2CHTR2BCYP2D6
Glycolic Acid SCHEMBL174349 0.78 HTR2C (0.45) MLNRHTR2AHTR2CHTR2BCYP2D6
Succinic Acid SCHEMBL174914 0.78 HTR2C (0.45) ALDH1A1MLNRHTR2AHTR2CHTR2B
SCHEMBL162032 0.77 HTR2C (0.57) MLNRHTR2AHTR2CHTR2BCYP2D6
Orotic Acid SCHEMBL162920 0.77 ALDH1A1 (0.45) ALDH1A1LMNAGPR84HTR2AHTR2C
Bromide SCHEMBL174563 0.76 HTR2C (0.55) MLNRHTR2AHTR2CHTR2BCYP2D6
Adipic Acid SCHEMBL173690 0.76 HTR2C (0.42) MLNRHTR2AHTR2CHTR2BCYP2D6
Sulfuric Acid SCHEMBL174597 0.75 MLNR (0.52) MLNRHTR2AHTR2CHTR2BCYP2D6
Phosphoric Acid SCHEMBL174207 0.75 HTR2C (0.47) MLNRHTR2AHTR2CHTR2BCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611449-A1 ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT Arena Pharmaceuticals, Inc. (US) 2013-07-10 EP disclosed
WO-2012030939-A1 ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT ARENA PHARMACEUTICALS, INC. (US) 2012-03-08 WO disclosed